Live Breaking News & Updates on Pronto

Stay informed with the latest breaking news from Pronto on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pronto and stay connected to the pulse of your community

Looking Ahead: Future Perspectives on AL Amyloidosis

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.

Vaishali-sanchorawala , Jeffrey-zonder , Heather-landau , Peer-exchange , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al , Nexicart-1

NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

United-states , American , Vaishali-sanchorawala , Heather-landau , Jeffrey-zonder , Peer-exchange , American-society-of-hematology , American-society , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab

Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

United-states , American , Vaishali-sanchorawala , Heather-landau , Jeffrey-zonder , Peer-exchange , American-society-of-hematology , American-society , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab

The Potential Role of CAR T Therapy in AL Amyloidosis

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.

Heather-landau , Jeffrey-zonder , Vaishali-sanchorawala , Peer-exchange , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al , Nexicart-1

AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients diagnosed with Mayo stage IV AL amyloidosis.

Transforming-outcomes , Precision-medicine , Targeted-therapies , Mayo-stage , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al

Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.

Transforming-outcomes , Precision-medicine , Targeted-therapies , Treatment-approaches , Abs-targeting-amyloid-deposits , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto

Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

Faculty delve into potential challenges related to the management of patients with AL amyloidosis and cardiac involvement, discussing the associated prognostic implications.

Transforming-outcomes , Precision-medicine , Targeted-therapies , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al , Nexicart-1

The Role of Cardiac Staging in Patients with AL Amyloidosis

A panel of expert oncologists discuss the importance of cardiac staging for patients with AL amyloidosis and it’s role in guiding overall treatment.

Transforming-outcomes , Precision-medicine , Targeted-therapies , Cardiac-staging , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al

Optimizing Treatment Management Strategies in AL Amyloidosis with CD-38-Directed mAbs

Faculty share insights into the treatment strategies using CD-38-directed monoclonal antibodies in patients with AL amyloidosis.

Transforming-outcomes , Precision-medicine , Targeted-therapies , Treatment-management-strategies , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al

Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

Jeffrey Zonder, MD provides an overview of treatment strategies using monoclonal antibodies for the treatment of AL amyloidosis.

Jeffrey-zonder , Transforming-outcomes , Precision-medicine , Targeted-therapies , Strategies-using-monoclonal-antibodies , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto